Brexanolone Injection (Zulresso)

Brexanolone (Zulresso) is covered only for adults (≥18 years) with moderate-to-severe postpartum depression within 6 months postpartum and is excluded for non-PPD indications, pregnant patients, those <18 years, >6 months postpartum, or with mild depression. Approval requires a one-time continuous 60‑hour IV infusion per the FDA dosing schedule, prescribed by or in consultation with a psychiatrist or OB‑GYN, with documentation of diagnosis, postpartum timing, pregnancy status, age, planned dosing, and REMS/safety compliance.

"Zulresso is indicated for the treatment of postpartum depression (PPD) in adults."

Sign up to see full coverage criteria, indications, and limitations.